Pink Sheet Podcast Special: Why The US Approves Most New Drugs Before The EU
Executive Summary
Pink Sheet reporter and editors discuss the impact of a US and EU drug approvals analysis that found the US FDA still clears many novel products first, including most new cell and gene therapies and cancer treatments.
Pink Sheet Executive Editor Derrick Gingery, Managing Editor Bridget Silverman, Interim Editor in Chief Nielsen Hobbs, Executive Editor Ian Schofield, and Senior Writer Francesca Bruce consider the results of an analysis of regulatory tracker data that found the US continues to approve most novel drugs before the European Union. They discuss why the gap persists in cell and gene therapy, as well as oncology, even though regulatory agencies can review some of the applications at the same time as the US Food and Drug Administration.
More On This Topic From The Pink Sheet
-
Pharma Looks To America First: US FDA Holds Overwhelming Lead Over EMA In Novel Approvals
-
US FDA Offers Faster Route To Market Than EMA: Details On All 108 Approvals
This and other podcasts are available on the Pink Sheet podcast page, as well as the Citeline channel on Apple Podcasts, Google Podcasts, SoundCloud, TuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.